Definium Therapeutics (DFTX) Gains from Investment Securities (2021 - 2026)
Definium Therapeutics (DFTX) reported Gains from Investment Securities of -$118000.0 for Q1 2026, down 1280.0% year-over-year from $10000.0 in Q1 2025, and down 594.12% on a QoQ basis from -$17000.0 in Q4 2025.
Definium Therapeutics (DFTX) has 6 years of Gains from Investment Securities data on file, last reported at -$118000.0 in Q1 2026.
- Quarterly Gains from Investment Securities fell 1280.0% year-over-year to -$118000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.6 million (up 175.05% YoY) and the FY2025 annual result came in at -$30000.0, down 155.56% from the prior year.
- Gains from Investment Securities retreated to -$118000.0 in Q1 2026 per DFTX's latest filing, from -$17000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $32.9 million in Q1 2024 and bottomed at -$13.4 million in Q2 2024.
- The 5-year median for Gains from Investment Securities is -$17000.0 (2025), against an average of $1.0 million.
- Peak annual rise in Gains from Investment Securities reached 182838.89% in 2024, while the deepest fall reached 18490.0% in 2024.
- Tracing DFTX's Gains from Investment Securities over 5 years: stood at -$8.2 million in 2022, then soared by 100.73% to $60000.0 in 2023, then tumbled by 18490.0% to -$11.0 million in 2024, then jumped by 99.85% to -$17000.0 in 2025, then plunged by 594.12% to -$118000.0 in 2026.
- Per Business Quant, the three latest DFTX Gains from Investment Securities figures stand at -$118000.0 (Q1 2026), -$17000.0 (Q4 2025), and $22.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -118,000.00 |
| Mar 31, 2026 | -118,000.00 |
| Dec 31, 2025 | -17,000.00 |
| Dec 31, 2025 | -17,000.00 |
| Sep 30, 2025 | 22.55 Mn |
| Sep 30, 2025 | 22.55 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Jun 30, 2025 | 2.23 Mn |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | -11.03 Mn |
| Dec 31, 2024 | -11.03 Mn |
| Sep 30, 2024 | -8.36 Mn |
| Sep 30, 2024 | -8.36 Mn |
| Jun 30, 2024 | -13.45 Mn |
| Jun 30, 2024 | -13.45 Mn |
| Mar 31, 2024 | 32.89 Mn |
| Mar 31, 2024 | 32.89 Mn |
| Dec 31, 2023 | 60,000.00 |
| Dec 31, 2023 | 60,000.00 |
| Sep 30, 2023 | -3.02 Mn |
| Sep 30, 2023 | -3.02 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | -18,000.00 |
| Mar 31, 2023 | -18,000.00 |
| Dec 31, 2022 | -8.25 Mn |
| Dec 31, 2022 | -8.25 Mn |
| Mar 31, 2022 | 407,000.00 |
| Mar 31, 2022 | 407,000.00 |
| Sep 30, 2021 | 27,000.00 |
| Sep 30, 2021 | 27,000.00 |
| Jun 30, 2021 | 67,000.00 |
| Jun 30, 2021 | 67,000.00 |
| Mar 31, 2021 | 19,000.00 |
| Mar 31, 2021 | 19,000.00 |